

Tumor-Type Agnostic, Targeted Therapies: BRAF Inhibitors Join the Group

Semir Vranic^{1,2}, Gargi D. Basu³, David W. Hall³, Zoran Gatalica^{3,4}

¹College of Medicine, QU Health, Qatar University, Doha, Qatar, ²Department of Medical Sciences, Academy of Sciences and Arts of Bosnia and Herzegovina, Sarajevo, Bosnia and Herzegovina, ³Exact Sciences, Phoenix, Arizona, United States of America, ⁴Department of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States of America

Correspondence: *semir.vranic@gmail.com; svranic@qu.edu.qa*; Tel.: + 974 4403 7873

Received: 2 November 2022; **Accepted:** 29 December 2022

Abstract

In the present review, we briefly discuss the breakthrough advances in precision medicine using a tumor-agnostic approach and focus on BRAF treatment modalities, the mechanisms of resistance and the diagnostic approach in cancers with *BRAF* mutations. Tumor-type agnostic drug therapies work across cancer types and present a significant novel shift in precision cancer medicine. They are the consequence of carefully designed clinical trials that showed the value of tumor biomarkers, not just in diagnosis but in therapy guidance. Six tumor-agnostic drugs (with seven indications) have been approved through October 2022 by FDA. The first tumor-agnostic treatment modality was pembrolizumab for MSI-H/dMMR solid tumors, approved in 2017. This was followed by approvals of larotrectinib and entrectinib for cancers with *NTRK* fusions without a known acquired resistance mutation. In 2020, pembrolizumab was approved for all TMB-high solid cancers, while a PD-L1 inhibitor dostarlimab-gxly was approved for dMMR solid cancers in 2021. A combination of BRAF/MEK inhibitors (dabrafenib/trametinib) was approved as a tumor-agnostic therapy in June 2022 for all histologic types of solid metastatic cancers harboring *BRAF*^{V600E} mutations. In September 2022, RET inhibitor selpercatinib was approved for solid cancers with *RET* gene fusions. **Conclusion.** Precision cancer medicine has substantially improved cancer diagnostics and treatment. Tissue type-agnostic drug therapies present a novel shift in precision cancer medicine. This approach rapidly expands to provide treatments for patients with different cancers harboring the same molecular alteration.

Key Words: Precision Medicine ■ Targeted Therapy ■ BRAF ■ BRAF Inhibitors ■ Molecular Diagnostics.

Introduction

Precision Medicine and Tumor-Agnostic Approach

Precision (or personalized) medicine in oncology represents a novel approach to cancer treatment. It implies using the right anticancer drug for the right patient at the right time. In contrast to the traditional oncologic treatment, this innovative approach considers individual differences in patients' genes, environment and lifestyle. Precision medicine was coined in 2011 by the USA's National Research Council's (NRC) report "Towards Precision Medicine" (1). In 2015-2020,

290 different precision and matched clinical trials were conducted (2), resulting in the approval of numerous targeted treatment modalities for various solid and hematologic malignancies; the list is provided here (3).

Much of the progress in precision medicine is due to rapid advances in high-throughput genomic sequencing technologies (e.g., next-generation sequencing/NGS) that enabled clinical implementation of assays. These assays can rapidly interrogate cancers for various molecular genomic alterations and targetable biomarkers and allow for more appropriate clinical decision-making and patient outcomes (4).

The precision medicine approach has led to a substantially higher proportion of responding cancer patients, with markedly improved clinical outcomes compared with traditional clinical trials involving unselected patients (5). In particular, clinical trials based on comprehensive molecular profiling may provide “customized multidrug regimens” with a substantial positive impact on the outcome of hard-to-treat and refractory cancers (6). Tissue/tumor type-agnostic drug therapies present a significant, albeit gradual, shift in precision cancer medicine. It is a consequence of carefully designed clinical trials showing the value of tumor biomarkers, not just in diagnosis but also in therapy guidance. Advances in molecular-genetic testing capabilities coupled with understanding complex molecular pathways interactions have led to the stratification of histologically diverse malignancies into biomarker/pathway-similar tumors. Three essential criteria should be fulfilled for tumor agnostic treatment: (1): Cancers must be enriched for at least one genomic alteration; (2) Such an alteration should be predictive of response to a matched therapy, (3) and the genomic alterations should be found across the cancers (7). Tissue type-agnostic drugs are usually assessed in “basket trials” in which small patient cohorts with diverse cancers are treated with the same targeted therapy (8).

Consequently, most basket trials are prospective phase II clinical trials designed to assess durable and objective therapeutic responses to a targeted treatment across different histologic cancer subtypes (9). Up to 2019, 49 basket trials were completed and their results were published (10). Our literature search revealed 76 different basket trials registered in the database ClinicalTrials.gov, most of which are related to cancer treatment (11).

The Food and Drug Administration (FDA) approved six different agnostic-based drugs (seven indications) in oncology from the period 2017 – October 2022 (12) (summarized in Table 1). The first drug approved in 2017 in a tissue-agnostic manner was pembrolizumab for the treatment of unresectable or metastatic solid tumors that have been identified as a microsatellite instability-high

(MSI-H) or mismatch repair deficient (dMMR) (13, 14). Three years later, FDA approved pembrolizumab for adult and pediatric patients with advanced and/or metastatic solid tumors exhibiting a high tumor mutational burden (TMB) (defined as ≥ 10 mutations/Mb) (15, 16). In 2018, larotrectinib was approved for pediatric and adult tumors harboring neurotrophic tyrosine receptor kinase (NTRK) gene fusions without a known acquired resistance mutation (17, 18), while another NTRK inhibitor, entrectinib, was approved in August 2019 for a similar indication (Table 1) (19, 20). In 2021, FDA granted accelerated approval for the PD-L1 inhibitor dostarlimab-gxly for adult patients having dMMR advanced or recurrent solid cancers (21, 22). FDA also approved the VENTANA MMR RxDx assay as a companion diagnostic (CDx) test to select patients with dMMR solid cancers for treatment with dostarlimab-gxly. In June 2022, FDA granted accelerated approval to dabrafenib in combination with trametinib for the treatment of adult and pediatric patients ≥ 6 years of age with unresectable or metastatic solid tumors with *BRAF*^{V600E} mutations who have progressed following prior treatment and have no satisfactory alternative treatment options (Table 1) (23). This approval was based on marked therapeutic responses to targeted BRAF/MEK inhibition of various solid malignancies with *BRAF*^{V600E} mutations, including low-grade gliomas, biliary, gynecological and gastrointestinal cancers (24-26).

Highly potent RET inhibitors were developed, targeting the *RET* oncogene that encodes a receptor-type tyrosine kinase. *RET* (rearranged during transfection) acts as an essential oncogene in several cancers, including medullary thyroid, non-small cell lung (NSCLC), pancreatic, breast, and ovarian carcinomas (27). *RET* is usually rearranged via mutations or gene fusions (28). FDA has already approved the RET-inhibitor selpercatinib for RET-positive (fused or mutated) NSCLC, medullary thyroid and differentiated thyroid carcinomas (29), while another RET inhibitor pralsetinib was approved in 2020 for metastatic RET-fused NSCLC (30). In September 2022, FDA granted accelerated approval for selpercatinib for treating

Table 1. Overview of the Agnostic-Based Approved Targeted Treatments in Oncology

Name of the drug(s)	Year of approval	Mechanism of action	Indications
Pembrolizumab	2017	PD-1 inhibition	Adult and pediatric patients With solid cancers harboring MSI-H/dMMR status
Larotrectinib	2018	pan-TRK (NTRK1-3) inhibition	Adult and pediatric patients with NTRK1-3-fused solid cancers
Entrectinib	2019	NTRK1-3, ALK, and ROS1 inhibition	Adult and pediatric patients with NTRK1-3-fused solid cancers
Pembrolizumab	2020	PD-1 inhibition	Adult and pediatric patients with TMB-H solid cancers*
Dostarlimab-gxly	2021	PD-1-PD-L1/PD-L2 inhibition	Adult patients with dMMR recurrent or advanced solid cancers
Dabrafenib and trametinib	2022	BRAF and MEK (MAP2K1) inhibition	Metastatic solid cancers with <i>BRAF</i> ^{V600E} mutations
Selpercatinib	2022	RET kinase inhibition	Adult patients with locally advanced or metastatic solid cancers with <i>RET</i> gene fusions

TMB-H defined as ≥ 10 mutations/Mb; PD-1=Programmed cell death protein 1; NTRK1-3=Neurotrophic Tyrosine Receptor Kinase 1-3; MSI-H=Microsatellite instability-high; dMMR=Deficient mismatch repair; TMB-H=Tumor mutational burden high.

locally advanced or metastatic solid cancers harboring *RET* gene fusions. The tissue type-agnostic approval was based on the LIBRETTO-001 basket trial enrolling 45 patients with colorectal, breast, pancreatic, salivary gland, ovarian, small intestine, and cholangiocarcinomas, cancer of unknown primary, soft tissue sarcoma, and bronchial carcinoid (31). The basket trial revealed that selpercatinib exhibited clinically impactful activity in the *RET* fusion-positive tumor-agnostic patients, with a safety profile similar to the one previously reported for selpercatinib (31).

Herein, we review the distribution of *BRAF* mutations and other genomic alterations across tumor types, methods of detection and potential pitfalls and caveats associated with biomarkers testing.

BRAF and Precision Medicine

BRAF Gene

The *BRAF* gene (B-Raf proto-oncogene, serine/threonine kinase), located on chromosome 7q34, is a constitutive part of the mitogen-activated protein kinase (MAPK/ERK) signaling pathway involved in cancer initiation and progression via cell survival and proliferation (Figure 1) (32). The *BRAF* gene encodes a cytoplasmic protein with

serine-threonine kinase activity. BRAF is usually activated via surface ligand binding to receptors with tyrosine kinase activity, such as Epidermal Growth Factor Receptor 1 (EGFR/HER1) or Human Epidermal Growth Factor Receptor 2 (HER2/ERBB2), followed by the activation of RAS-family GTPases. This chain of reactions leads to the dimerization of BRAF with BRAF or CRAF and activation of downstream components of the MAPK/ERK pathway MEK1/2 and ERK1/2 (Figure 1). The activation of the MAPK pathway upregulates various transcription factors involved in cellular survival, proliferation, and growth (32).

BRAF Mutations and Other Genomic Alterations

BRAF is frequently mutated in human cancer, with an estimated frequency of ~3-7% (33-37). Since 2002 when Davies et al. described *BRAF* mutations in a subset of human neoplasms (33), numerous studies explored *BRAF* status in various solid tumors (melanoma, carcinomas, brain tumors) and hematological malignancies (e.g., hairy cell leukemia, multiple myeloma, systemic histiocytoses) (35, 38-41). *BRAF* mutations have also been described in various soft tissue tumors, including malignant peripheral nerve sheath tumors (~10%), Ewing sarcomas (3%), and gastrointestinal stromal




Figure 1. Schematic of MAPK signal (black/dark blue) and related (gray) pathways. Wild type *BRAF* (in dark blue) acts as a dimer (with *BRAF* or *CRAF*) to activate MEK in response to activation of RAS, eventually leading to cell proliferation. *BRAF* mutations (light blue) may act in a RAS-independent manner as monomers (Class I) or dimers (Class II), or in a RAS-dependent manner as a dimer (with wild type *BRAF/CRAF*). Mutant *BRAF* (in light blue) appears to be a stronger activator of MEK than wild type, with Class III less strong than classes I and II. *BRAF* inhibitor resistance may involve mutations at several of the genes encoding the proteins shown (see text).

tumors (7%) [reviewed in (42)]. *BRAFV600E* mutations were also detected in rare, poorly differentiated sarcomas with spindle cell morphology (43).

Tumors with the highest *BRAF* mutation rate (~50-80%) include malignant melanoma, papillary thyroid carcinoma, pilocytic astrocytoma and low-grade serous carcinoma of the ovary (35). However, in other tumors, the frequency of *BRAF* gene mutations is usually seen in the minority of cases (<5%) (44-47). *BRAF* mutations have also

been described in several benign tumors, such as melanocytic nevi, metanephric adenomas, and pituitary adenomas, as well as in low-grade neoplasms, such as Erdheim-Chester disease and Langerhans cell histiocytosis (48-51) or locally aggressive neoplasms such as ameloblastomas and craniopharyngiomas (52-55). The data from molecular studies indicate that *BRAF* mutations alone cannot initiate malignant transformation and are usually preceded by the inactivation of

tumor suppressor genes (e.g., *CDKN2A*, *PTEN* and *BAP1*), *TERT* promoter mutations or inactivation of genes involved in DNA repair (48, 56-58).

Based on their effects on the MAPK pathway, three classes of *BRAF* gene mutations have been described: Class 1, associated with kinase activity (e.g., *BRAF* V600E, V600K/D/R/M mutations); Class 2 (e.g., K601E, K601N, K601T, L597Q, L597V, L485F, G469A, G469V, G469R, G464V, G464E, and fusions), with constitutively active dimers (codons 601, 597, 469, and 464) (Figure 1); These mutations are resistant to vemurafenib but may be sensitive to MEK inhibitors. Class 3 (D287H, V459L, G466V, G466E, G466A, S467L, G469E, N581S, N581I, D594N, D594G, D594A, D594H, F595L, G596D, and G596R), with low-to nil kinase activity/RAS-dependent mutations, frequently affect exons 11 and 15 and these mutations are commonly observed in non-small cell lung and colorectal carcinomas (48, 59); these mutations are sensitive to MEK inhibitors. Class 1 mutations are usually mutually exclusive with other driver mutations (e.g., *EGFR*, *KRAS*, *ALK*). The majority (~80-90%) of *BRAF* mutations are class 1 missense V600E mutations (35, 60). V600E mutation is caused by the transversion of T to A nucleotide 1799 (T1799A), resulting in a substitution of valine (V) for glutamic acid (E) at position 600. The remaining (15-20%) of *BRAF* mutations include V600K, V600R, V600M, V600D and non-V600 mutations (e.g., K601, D594N, G469). Some of these mutations may also be amenable to treatment with *BRAF* and/or MEK inhibitors (e.g., V600K). However, the efficacy appears to be lower compared to the sensitivity of V600E mutations (61). In contrast, some other mutations (e.g., G469 mutations) are predictors of resistance to anti-*BRAF* therapies but sensitivity to *EGFR* inhibitors (57, 62, 63).

In addition, rare *BRAF* gene fusions have been described in various cancer subtypes (frequency 0.3%), particularly in Spitzoid melanomas, pilocytic astrocytomas, papillary thyroid carcinomas, acinar pancreatic carcinomas, gastric carcinomas, serous ovarian carcinomas (both low- and high-grade), salivary gland carcinomas, and histiocytic

neoplasms (pediatric and adult xanthogranulomas) (64-73). *BRAF* gene fusions and point mutations have recently been found in a subset of adult and pediatric soft tissue tumors with spindle cell morphology and infantile fibrosarcoma-like growth pattern (74-76). Antonescu also described a poorly differentiated sarcoma with a *BRAF* gene rearrangement; the neoplasm exhibited a whorling growth pattern with the spindle cells within a fibrotic stroma (77). Various *BRAF* gene fusions have also been described in other sarcoma morphologies (78-80). *BRAF*-fused cancers confer resistance to *BRAF* and *EGFR* inhibitors but may be sensitive to MEK or pan-RAF inhibitors (65, 81-88).

Not all cancers with *BRAF* mutations are responsive to *BRAF* inhibitors. Thus, in colorectal carcinoma, there is a strong interplay between *BRAF* and *EGFR*, and *BRAF* inhibitors alone are ineffective due to the activation of the *EGFR* pathway. However, a combined treatment with *BRAF*, MEK and *EGFR* inhibitors may overcome the potential resistance and induce a much better therapeutic response (89). In contrast, *BRAF* inhibitors effectively inhibit melanoma cells due to the low expression of *EGFR* receptor in these cells (89).

BRAF mutations have been associated with a more aggressive clinical course and poor outcomes in cancer patients (90-93). *BRAF* mutations are also strong predictors of response to anti-*BRAF* treatment modalities, such as *BRAF* (vemurafenib, dabrafenib and encorafenib) and MEK inhibitors (trametinib, cobimetinib, binimetinib) alone or in combination (45, 94). *BRAF* inhibitors and five combinations of a *BRAF* inhibitor plus an additional agent(s) to manage cancers such as melanoma, non-small cell lung cancer, anaplastic thyroid cancer, colorectal cancer, and Erdheim-Chester disease have been approved (Table 2). To date, each regimen is effective only in patients with tumors harboring *BRAF* V600 mutations, and the benefit duration is often short-lived. Further limitations preventing optimal management of *BRAF* mutant cancers are that treatments of non-V600 *BRAF* mutations have been less profound. Combined therapy is likely

Table 2. Overview of the Cancers with Approved Anti-BRAF Treatment Modalities

Tumor type (indication)	Drug(s)/Combinations	Predictive testing
Malignant melanoma	BRAF/MEK inhibitors /vemurafenib, dabrafenib, encorafenib/trametinib, cobimetinib, binimetinib/	<i>BRAF</i> mutational status
Colorectal carcinoma	BRAF/MEK/EGFR inhibitors (encorafenib/binimetinib/cetuximab)	<i>KRAS</i> , <i>NRAS</i> and <i>BRAF</i> mutational status
Non-small cell lung carcinoma	BRAF/MEK inhibitors (dabrafenib/trametinib)	<i>BRAF</i> mutational status
Anaplastic thyroid carcinoma	BRAF/MEK inhibitors (dabrafenib/trametinib)	<i>BRAF</i> mutational status
Erdheim-Chester Disease	BRAF inhibitors (vemurafenib)	<i>BRAF</i> mutational status
Solid tumors	BRAF/MEK inhibitors (dabrafenib/trametinib)	<i>BRAF</i> ^{V600E} mutations

necessary to overcome resistance mechanisms, but multi-drug treatment options are often too toxic (95). The combination of a BRAF inhibitor and a MEK inhibitor (which acts by inhibiting kinases further downstream of BRAF in the MAPK pathway) substantially inhibits MAPK signaling with a more potent and durable inhibition of MAPK/ERK signaling and delayed acquired resistance (96-98). Dual MAPK pathway inhibition is a standard treatment option for *BRAF*-mutated melanoma (94, 99). Multiple studies also revealed the therapeutic benefit of vemurafenib in patients with several non-melanoma, *BRAF*-mutated cancer types such as NSCLC, Erdheim-Chester disease, Langerhans' cell histiocytosis, and hairy cell leukemia (39, 44, 100).

Resistance to BRAF/MEK Inhibitors

The resistance to BRAF/MEK inhibitors is an emerging problem associated with various genetic and/or epigenetic alterations within the two major signaling pathways, RAF/MEK/ERK and PIK3CA/PTEN/AKT (Figure 1) (35, 101-104). While the intrinsic resistance to BRAF/MEK inhibitors is relatively rare, the acquired resistance (following the treatment) is widespread and nearly inevitable. In particular, mutations of *KRAS*, *NRAS*, *MAP2K1*, and *MAP2K2*, along with *BRAF* amplifications (MAPK reactivation or "addiction"), contribute to the resistance to BRAF inhibitors [(reviewed in (57, 104)]. Another potential resistance

mechanism is a *BRAF*^{V600E} splice variant that promotes RAF dimerization (105). Mutations within the PIK3CA/PTEN signaling pathway involving *PIK3CA*, *PTEN*, *AKT1*, *PIK3R1*, *PIK3R2*, and *AKT3* genes are also involved in the resistance to BRAF inhibitors. Genetic alterations of *RAC1*, *CDK4*, *CCND1*, and *c-MET* genes also contribute to the resistance to anti-BRAF treatment modalities. Recently, androgen receptor (AR) expression has been described as a potential resistance mechanism in preclinical (animal) models with significantly reduced anticancer activity of BRAF/MEK inhibitors in male mice compared with female mice (106). The study also revealed significantly higher AR expression in melanomas affecting male mice than female mice. The preclinical observations were further translated and confirmed in a clinical cohort of melanoma patients treated with BRAF/MEK inhibitors (106). Further studies should confirm whether androgen suppression could be combined with BRAF/MEK inhibitors in melanoma patients. In NSCLC, the most common causes of resistance to BRAF/MEK inhibitors are mutations of *MEK1*, *PTEN*, *NRAS*, and *KRAS* genes (107).

Epigenetic or transcriptome-based changes were speculated to be the likely drivers of the resistance to BRAF inhibitors among ~40% of melanomas that progressed on the treatment and lacked any identifiable genetic abnormality to explain such resistance (104). Among these resistance mechanisms, DNA methylation, post-translational

histone modifications, and various miRNAs appear to play prominent roles (108).

Diagnostic Approaches for BRAF Mutations

For treatment purposes, a routine determination of *BRAF* status is the standard of care (99, 109-111). *BRAF* analysis is usually performed on formalin-fixed paraffin-embedded tissue (FFPE) samples (either primary or metastatic). If FFPE of the primary or metastatic cancer is unavailable, a blood sample or liquid biopsy using circulating tumor DNA (ctDNA) may be an alternative (Guardant 360, Table 3). Although ctDNA presents an essential innovation in cancer diagnostics and management (e.g., diagnosis and molecular profiling of advanced non-small cell lung cancer or the monitoring of *BRAF* status in melanoma patients during the targeted treatment with BRAF/MEK inhibitors) (34703985), it has certain limitations, including lower sensitivity (47-84%) compared with the PCR-based assays performed on FFPE (112-116).

BRAF analysis is usually performed using various DNA-based molecular assays. The FDA has also approved several diagnostic assays for detecting *BRAF* mutations as CDx tests or authorized assays (summarized in Table 3). Various laboratory-developed assays have also been developed and routinely utilized for *BRAF* gene testing in patients with melanoma and other cancers with approved anti-BRAF treatment modalities (Table 2) (57).

Among the DNA/RNA-based assays, Sanger sequencing, pyrosequencing, mutation-specific Polymerase Chain Reaction (PCR) and mutation-specific real-time PCR, digital PCR (dPCR), High-Resolution Melting curve analysis (HRM), Matrix Assisted Laser Desorption Ionization-Time Of Flight Mass Spectrometry (MALDI-TOF MS; Sequenom), and many Next-Generation Sequencing (NGS) based assays are available (117). Each of these assays has its characteristics and performances but shares very high sensitivity and specificity (~85-100%) in detecting genomic alterations, including *BRAF* gene mutations (117).

Some of these assays were also approved by FDA as CDx tests (summarized in Table 3).

The Cobas 4800 BRAF V600 Mutation Test (Roche Molecular Systems, Inc.) was the first FDA-approved CDx for *BRAF* assessment. This test was used in the clinical trial that led to the approval of vemurafenib by FDA and later by the European Medicines Agency (EMA) (118). The Cobas 4800 BRAF V600 Mutation Test was approved for the vemurafenib/cobimetinib combination, while another RT-PCR-based assay approved for dabrafenib/trametinib combination is the THxID-BRAF kit (bioMerieux Inc.) (Table 3). The therascreen BRAF V600E RGQ PCR Kit (QIAGEN GmbH) is the third RT-PCR-based assay approved by FDA as a CDx. It assesses *BRAFV600E* mutations in patients with colorectal cancer for the potential treatment with encorafenib in combination with cetuximab (a monoclonal antibody against EGFR).

NGS refers to large-scale (high-throughput) DNA and RNA sequencing technology that allows for querying the whole genome, the exons within all known genes (whole exome), or only exons of selected genes (target panel). The use of NGS revolutionized cancer genomic profiling and has become a cornerstone diagnostic tool in precision medicine management (119, 120). It is a highly efficient and precise assay (sensitivity of 98% and specificity of 100%) that enables comprehensive cancer genomic profiling. It is, therefore, a reliable and affordable tool for detecting various genomic alterations, including those affecting the *BRAF* gene (117). Several NGS-based assays achieved either CDx status or were authorized by FDA. These include CDx assays FoundationOne CDx (by Foundation Medicine, Inc.), and Oncomine Dx Target Test (by Life Technologies Corporation), and FDA-authorized assays MSK-IMPACT (by Memorial Sloan Kettering Center), and Guardant360 CDx (by Guardant Health, Inc.) (Table 3). These assays include gene panels of various sizes (from 55 to 505 genes) and also provide additional valuable information about other predictive biomarkers (e.g., tumor mutational burden or microsatellite instability status) (See Table 3

Table 3. The List of FDA-Approved Companion Diagnostic and Authorized Tests/Assays for *BRAF* Testing [Adopted and Modified From (4)].

Test (Manufacturer)	Indication(s)	Diagnostic method
CDx tests/assays		
Cobas 4800 <i>BRAF</i> V600 Mutation Test (Roche Molecular Systems, Inc.)	Malignant melanoma (covering V600E and V600K mutations, respectively)	PCR-based assay
FoundationOne CDx (Foundation Medicine, Inc.)	NSCLC and melanoma (covering V600E and V600 mutations, respectively)	NGS based assay
Oncomine Dx Target Test (Life Technologies Corporation)	NSCLC (covering V600E mutations)	NGS based assay
The theascreen <i>BRAF</i> V600E RGQ PCR Kit (QIAGEN GmbH)	Colorectal cancer (covering V600E mutations)	Real-time PCR
The THxID- <i>BRAF</i> kit (bioMerieux Inc.)	Malignant melanoma (covering V600E and V600K mutations)	Real-time PCR
FDA-authorized tests/assays		
MSK-IMPACT (Memorial Sloan Kettering/MSK/)	Melanoma and other cancers with <i>BRAF</i> and other mutations (the panel of 505 genes)	NGS based assay
Guardant360 CDx (Guardant Health, Inc.)	NSCLC, CRC (<i>BRAF</i> and 54 additional targetable genes)	NGS assay based on liquid biopsy

PCR=Polymerase chain reaction; CDx=Companion diagnostics; NGS=Next-generation sequencing; NSCLC=Non-small cell lung carcinoma; CRC=Colorectal carcinoma.

with the list of FDA-approved CDx assays based on NGS technology).

The VE1 antibody is the only immunohistochemical assay currently available for *BRAF* protein testing and detection (57) but has not received regulatory approval as a CDx despite its widespread availability. *BRAF* V600E-specific antibody VE1 has a good concordance with detecting the *BRAF*V600E mutation by some genetic tests (34).

A meta-analysis based on 21 studies covering 1687 melanoma cases confirmed an excellent diagnostic utility of the VE1 antibody for detecting *BRAF*V600E mutation, with a sensitivity of 0.96 and specificity of 1.00 (121). Similar performance of the VE1 antibody was reported in colorectal (122-124), thyroid carcinomas (125-128), hairy cell leukemias (129, 130) (Figure 2A-B), and low-grade serous ovarian neoplasms (131).




Figure 2A-B. (A): Hematoxylin and Eosin (H&E) slide of a case of hairy cell leukemia with a diffuse bone marrow infiltration (10x magnification); neoplastic cells harbored *BRAF*V600E mutation, which was confirmed immunohistochemically using VE1 antibody (40x magnification).

Our previous study, based on a cohort of diverse cancers, confirmed that the VE1 antibody is 100% sensitive and 91% specific for *BRAFV600E* protein and may serve as a good screening tool, especially in tumor types with a high proportion of *BRAFV600E* mutation (e.g., thyroid carcinoma, colorectal carcinoma, melanoma) (132). However, VE1 IHC screening in tumor types with a higher proportion of non-*BRAFV600E* mutation may not be feasible with a high proportion of false-negative results (133-135). For instance, lung adenocarcinomas may have a higher proportion of false negative results due to the finding of the D594V mutation. Rare actionable mutations (e.g., V600K) may also be missed using VE1 IHC alone (132, 136). The discrepancies between VE1 IHC and PCR assays have also been described in the kidney's *BRAFV600E*-mutated metanephric adenomas, pituitary adenomas, and Langerhans cell histiocytosis (51, 137, 138).

Although Martins-de-Barros et al. in the systematic review with a meta-analysis, reported an excellent diagnostic utility of VE1 IHC in ameloblastomas (139), several studies reported its low diagnostic value in maxillary ameloblastomas that are predominantly affected by non-*BRAFV600E*-mutations (52, 140).

Taken together, VE1 IHC appears to be an excellent screening assay, particularly for the detection of *BRAFV600E* mutations, but further confirmation with molecular (PCR)-based methods is still required for the targeted treatment with BRAF and/or MEK inhibitors.

Conclusions

Precision cancer medicine has substantially improved cancer diagnostics and treatment. Tissue type-agnostic drug therapies present a novel shift in precision cancer medicine. It is a consequence of carefully designed clinical trials showing the value of tumor biomarkers, not just in diagnosis but in therapy guidance. Six different tumor-agnostic treatment modalities have been approved for cancer treatment since 2017 when pembrolizumab was approved for MSI-H/dMMR solid

tumors regardless of their histotype. In June 2022, a combination of BRAF/MEK inhibitors (dabrafenib/trametinib) was approved in a tumor-agnostic fashion for all solid metastatic cancers harboring *BRAF^{V600E}* mutations. *BRAF* mutations affect ~3-7% of all cancers, with the highest prevalence in melanoma, papillary thyroid carcinoma, pilocytic astrocytoma, and low-grade serous ovarian carcinoma. However, a low prevalence ($\leq 5\%$) of *BRAF* mutations has been described in ~50 cancer subtypes. BRAF inhibitors alone or combined with MEK inhibitors have been approved and substantially improved the treatment of several cancers, including malignant melanoma, non-small cell lung cancer, anaplastic thyroid cancer, colorectal cancer, and Erdheim-Chester disease. The diagnosis of *BRAF* mutations remains a cornerstone of anti-BRAF treatment(s), and several highly sensitive and specific diagnostic assays were approved as CDx tests. Resistance to treatment represents an emerging issue among BRAF cancers, mainly when BRAF inhibitors are administered alone. Apart from mutations within MAPK/MEK and PIK3CA signaling pathways, novel and potentially targetable resistance causes have been recently described (androgen receptor overexpression). Further efforts are needed to translate these findings into clinical practice and improve the outcome of patients with *BRAF*-mutated cancers.

Conflict of Interest: Gargi D. Basu and David W. Hall are full-time employees and stockholders of Exact Sciences. Zoran Gatalica is a part-time employee of Exact Sciences. Semir Vranic declares no conflict of interest.

References

1. Council NR. Toward Precision Medicine: Building a Knowledge Network for Biomedical Research and a New Taxonomy of Disease. Washington, DC: The National Academies Press; 2011.
2. Hibino Y, Ito M, Satake T, Kondo S. Clinical benefits of precision medicine in treating solid cancers: European Society of Medical Oncology-Magnitude of Clinical Benefit Scale score-based analysis. *ESMO Open*. 2021;6(4):100187.
3. List of Targeted Therapy Drugs Approved for Specific Types of Cancer 2022 [cited 15 Oct 2022]. Available from:

- <https://www.cancer.gov/about-cancer/treatment/types/targeted-therapies/approved-drug-list>.
4. Vranic S, Gatalica Z. The Role of Pathology in the Era of Personalized (Precision) Medicine: A Brief Review. *Acta Med Acad.* 2021;50(1):47-57.
 5. Jardim DL, Schwaederle M, Wei C, Lee JJ, Hong DS, Eggermont AM, et al. Impact of a Biomarker-Based Strategy on Oncology Drug Development: A Meta-analysis of Clinical Trials Leading to FDA Approval. *J Natl Cancer Inst.* 2015;107(11):djv253.
 6. Sicklick JK, Kato S, Okamura R, Schwaederle M, Hahn ME, Williams CB, et al. Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study. *Nat Med.* 2019;25(5):744-50.
 7. Offin M, Liu D, Drilon A. Tumor-Agnostic Drug Development. *Am Soc Clin Oncol Educ Book.* 2018;38:184-7.
 8. Looney AM, Nawaz K, Webster RM. Tumour-agnostic therapies. *Nat Rev Drug Discov.* 2020;19(6):383-4.
 9. Hobbs BP, Pestana RC, Zabor EC, Kaizer AM, Hong DS. Basket Trials: Review of Current Practice and Innovations for Future Trials. *J Clin Oncol.* 2022;JCO2102285.
 10. Park JJH, Siden E, Zoratti MJ, Dron L, Harari O, Singer J, et al. Systematic review of basket trials, umbrella trials, and platform trials: a landscape analysis of master protocols. *Trials.* 2019;20(1):572.
 11. Basket trials 2022 [cited 15 Oct 2022]. Available from: <https://clinicaltrials.gov/ct2/results?cond=&term=basket+trial&cntry=&state=&city=&dist=>.
 12. Tumor-agnostic Drugs: American Cancer Society; 2022 [cited 15 Oct 2022]. Available from: <https://www.cancer.org/treatment/treatments-and-side-effects/treatment-types/tumor-agnostic-drugs.html>.
 13. Pembrolizumab (Keytruda) 5-10-2017 2017 [cited 15 Oct 2022]. Available from: <https://www.fda.gov/drugs/resources-information-approved-drugs/pembrolizumab-keytruda-5-10-2017>.
 14. Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. *N Engl J Med.* 2015;372(26):2509-20.
 15. FDA approves pembrolizumab for adults and children with TMB-H solid tumors 2020 [cited 15 Oct 2022]. Available from: <https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-pembrolizumab-adults-and-children-tmb-h-solid-tumors>.
 16. Marabelle A, Fakih M, Lopez J, Shah M, Shapira-Frommer R, Nakagawa K, et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEY-NOTE-158 study. *Lancet Oncol.* 2020;21(10):1353-65.
 17. FDA approves larotrectinib for solid tumors with NTRK gene fusions 2018 [cited 15 Oct 2022]. Available from: <https://www.fda.gov/drugs/fda-approves-larotrectinib-solid-tumors-ntrk-gene-fusions>.
 18. Drilon A, Laetsch TW, Kummar S, DuBois SG, Lassen UN, Demetri GD, et al. Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. *N Engl J Med.* 2018;378(8):731-9.
 19. FDA approves entrectinib for NTRK solid tumors and ROS-1 NSCLC 2019 [cited 15 Oct 2022]. Available from: <https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-entrectinib-ntrk-solid-tumors-and-ros-1-nsclc>.
 20. Doebele RC, Drilon A, Paz-Ares L, Siena S, Shaw AT, Farago AF, et al. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. *Lancet Oncol.* 2020;21(2):271-82.
 21. FDA grants accelerated approval to dostarlimab-gxly for dMMR advanced solid tumors 2021 [cited 15 Oct 2022]. Available from: <https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-dostarlimab-gxly-dmmr-advanced-solid-tumors>.
 22. Andre T, Berton D, Curigliano G, Ellard S, Pérez JMT, Arkenau H-T, et al. Safety and efficacy of anti-PD-1 antibody dostarlimab in patients (pts) with mismatch repair-deficient (dMMR) solid cancers: Results from GARNET study. *Journal of Clinical Oncology.* 2021;39(3 suppl):9-9.
 23. FDA grants accelerated approval to dabrafenib in combination with trametinib for unresectable or metastatic solid tumors with BRAF V600E mutation 2022 [cited 15 Oct 2022]. Available from: <https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-dabrafenib-combination-trametinib-unresectable-or-metastatic-solid>.
 24. Wen PY, Stein A, van den Bent M, De Greve J, Wick A, de Vos F, et al. Dabrafenib plus trametinib in patients with BRAF(V600E)-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial. *Lancet Oncol.* 2022;23(1):53-64.
 25. Wainberg ZA, Lassen UN, Elez E, Italiano A, Curigliano G, Braud FGD, et al. Efficacy and safety of dabrafenib (D) and trametinib (T) in patients (pts) with BRAF V600E-mutated biliary tract cancer (BTC): A cohort of the ROAR basket trial. *Journal of Clinical Oncology.* 2019;37(4 suppl):187-187.
 26. Salama AKS, Li S, Macrae ER, Park JI, Mitchell EP, Zwiebel JA, et al. Dabrafenib and Trametinib in Patients With Tumors With BRAF(V600E) Mutations: Results of the NCI-MATCH Trial Subprotocol H. *J Clin Oncol.* 2020;38(33):3895-904.
 27. Kohno T. SY21-3 RET-altered cancers: toward tumor agnostic therapy. *Annals of Oncology.* 2022;33:S445.
 28. Thein KZ, Velcheti V, Mooers BHM, Wu J, Subbiah V. Precision therapy for RET-altered cancers with RET inhibitors. *Trends Cancer.* 2021;7(12):1074-88.
 29. RETEVMO® (selpercatinib) capsules, for oral use 2021 [cited 15 Oct 2022]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213246s008lbl.pdf.

30. FDA approves pralsetinib for lung cancer with RET gene fusions 2020 [cited 15 Oct 2022]. Available from: <https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pralsetinib-lung-cancer-ret-gene-fusions>.
31. Subbiah V, Wolf J, Konda B, Kang H, Spira A, Weiss J, et al. Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial. *Lancet Oncol*. 2022;23(10):1261-73.
32. Dankner M, Rose AAN, Rajkumar S, Siegel PM, Watson IR. Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations. *Oncogene*. 2018;37(24):3183-99.
33. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. *Nature*. 2002;417(6892):949-54.
34. Jabbar KJ, Luthra R, Patel KP, Singh RR, Goswami R, Aldape KD, et al. Comparison of next-generation sequencing mutation profiling with BRAF and IDH1 mutation-specific immunohistochemistry. *Am J Surg Pathol*. 2015;39(4):454-61.
35. Pakneshan S, Salajegheh A, Smith RA, Lam AK. Clinico-pathological relevance of BRAF mutations in human cancer. *Pathology*. 2013;45(4):346-56.
36. Consortium APG. AACR Project GENIE: Powering Precision Medicine through an International Consortium. *Cancer Discov*. 2017;7(8):818-31.
37. Yi Q, Peng J, Xu Z, Liang Q, Cai Y, Peng B, et al. Spectrum of BRAF Aberrations and Its Potential Clinical Implications: Insights From Integrative Pan-Cancer Analysis. *Front Bioeng Biotechnol*. 2022;10:806851.
38. Gatalica Z, Bilalovic N, Palazzo JP, Bender RP, Swensen J, Millis SZ, et al. Disseminated histiocytoses biomarkers beyond BRAFV600E: frequent expression of PD-L1. *Oncotarget*. 2015;6(23):19819-25.
39. Tiacci E, Trifonov V, Schiavoni G, Holmes A, Kern W, Martelli MP, et al. BRAF mutations in hairy-cell leukemia. *N Engl J Med*. 2011;364(24):2305-15.
40. Badalian-Very G, Vergilio JA, Degar BA, MacConaill LE, Brandner B, Calicchio ML, et al. Recurrent BRAF mutations in Langerhans cell histiocytosis. *Blood*. 2010;116(11):1919-23.
41. Rustad EH, Dai HY, Hov H, Coward E, Beisvag V, Myklebost O, et al. BRAF V600E mutation in early-stage multiple myeloma: good response to broad acting drugs and no relation to prognosis. *Blood Cancer J*. 2015;5:e299.
42. Liu H, Nazmun N, Hassan S, Liu X, Yang J. BRAF mutation and its inhibitors in sarcoma treatment. *Cancer Med*. 2020;9(14):4881-96.
43. Seifert R, Bui M, Messina J. Mutated BRAF V600E in Poorly Differentiated Spindle Cell Malignancies Following the Initial Diagnosis of Melanoma in Another Site: A Diagnostic Challenge. *American Journal of Clinical Pathology*. 2014;142(suppl 1):A248.
44. Hyman DM, Puzanov I, Subbiah V, Faris JE, Chau I, Blay JY, et al. Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations. *N Engl J Med*. 2015;373(8):726-36.
45. Adashek JJ, Menta AK, Reddy NK, Desai AP, Roszik J, Subbiah V. Tissue-Agnostic Activity of BRAF plus MEK Inhibitor in BRAF V600-Mutant Tumors. *Mol Cancer Ther*. 2022;21(6):871-8.
46. Gatalica Z, Burnett K, Bender R, Feldman R, Vranic S, Reddy S. BRAF mutations are potentially targetable alterations in a wide variety of solid cancers. *European Journal of Cancer*. 2015;51:S31-S.
47. Gatalica Z, Xiu J, Swensen J, Vranic S. Comprehensive analysis of cancers of unknown primary for the biomarkers of response to immune checkpoint blockade therapy. *Eur J Cancer*. 2018;94:179-86.
48. Sholl LM. A narrative review of BRAF alterations in human tumors: diagnostic and predictive implications. *Precision Cancer Medicine*. 2020;3.
49. Yeh I, von Deimling A, Bastian BC. Clonal BRAF mutations in melanocytic nevi and initiating role of BRAF in melanocytic neoplasia. *J Natl Cancer Inst*. 2013;105(12):917-9.
50. Choueiri TK, Cheville J, Palescandolo E, Fay AP, Kantoff PW, Atkins MB, et al. BRAF mutations in metanephric adenoma of the kidney. *Eur Urol*. 2012;62(5):917-22.
51. Farzin M, Toon CW, Clarkson A, Sioson L, Gill AJ. BRAF V600E mutation specific immunohistochemistry with clone VE1 is not reliable in pituitary adenomas. *Pathology*. 2014;46(1):79-80.
52. Mendez LD, Wolsefer NS, Asa SL, Wasman J, Yoest JM, Stojanov IJ. The diagnostic utility of BRAF VE1 mutation-specific immunohistochemistry in ameloblastoma. *Mod Pathol*. 2022.
53. Kassab C, Zamler D, Kamiya-Matsuoka C, Gatalica Z, Xiu J, Spetzler D, et al. Genetic and immune profiling for potential therapeutic targets in adult human craniopharyngioma. *Clin Oncol Res*. 2019;2(3):2-8.
54. Brastianos PK, Santagata S. ENDOCRINE TUMORS: BRAF V600E mutations in papillary craniopharyngioma. *Eur J Endocrinol*. 2016;174(4):R139-44.
55. Brastianos PK, Shankar GM, Gill CM, Taylor-Weiner A, Nayyar N, Panka DJ, et al. Dramatic Response of BRAF V600E Mutant Papillary Craniopharyngioma to Targeted Therapy. *J Natl Cancer Inst*. 2016;108(2):djv310.
56. Damsky WE, Bosenberg M. Melanocytic nevi and melanoma: unraveling a complex relationship. *Oncogene*. 2017;36(42):5771-92.
57. Cheng L, Lopez-Beltran A, Massari F, MacLennan GT, Montironi R. Molecular testing for BRAF mutations to inform melanoma treatment decisions: a move toward precision medicine. *Mod Pathol*. 2018;31(1):24-38.

58. Huang FW, Hodis E, Xu MJ, Kryukov GV, Chin L, Garraway LA. Highly recurrent TERT promoter mutations in human melanoma. *Science*. 2013;339(6122):957-9.
59. Yao Z, Yaeger R, Rodrik-Outmezguine VS, Tao A, Torres NM, Chang MT, et al. Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS. *Nature*. 2017;548(7666):234-8.
60. Carter J, Tseng LH, Zheng G, Dudley J, Illei P, Gocke CD, et al. Non-p.V600E BRAF Mutations Are Common Using a More Sensitive and Broad Detection Tool. *Am J Clin Pathol*. 2015;144(4):620-8.
61. Menzer C, Menzies AM, Carlino MS, Reijers I, Groen EJ, Eigentler T, et al. Targeted Therapy in Advanced Melanoma With Rare BRAF Mutations. *J Clin Oncol*. 2019;37(33):3142-51.
62. Huo KG, Notsuda H, Fang Z, Liu NF, Gebregiorgis T, Li Q, et al. Lung Cancer Driven by BRAF(G469V) Mutation Is Targetable by EGFR Kinase Inhibitors. *J Thorac Oncol*. 2022;17(2):277-88.
63. Dahlman KB, Xia J, Hutchinson K, Ng C, Hucks D, Jia P, et al. BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors. *Cancer Discov*. 2012;2(9):791-7.
64. Ross JS, Wang K, Chmielecki J, Gay L, Johnson A, Chudnovsky J, et al. The distribution of BRAF gene fusions in solid tumors and response to targeted therapy. *Int J Cancer*. 2016;138(4):881-90.
65. Zanzwar S, Abeykoon JP, Dasari S, Ravindran A, Young JR, Acosta-Medina AA, et al. Clinical and therapeutic implications of BRAF fusions in histiocytic disorders. *Blood Cancer J*. 2022;12(6):97.
66. Jain P, Surrey LE, Straka J, Russo P, Womer R, Li MM, et al. BRAF fusions in pediatric histiocytic neoplasms define distinct therapeutic responsiveness to RAF paradox breakers. *Pediatr Blood Cancer*. 2021;68(6):e28933.
67. Chui MH, Chang JC, Zhang Y, Zehir A, Schram AM, Konner J, et al. Spectrum of BRAF Mutations and Gene Rearrangements in Ovarian Serous Carcinoma. *JCO Precis Oncol*. 2021;5:PO.21.00055.
68. Helgager J, Lidov HG, Mahadevan NR, Kieran MW, Ligon KL, Alexandrescu S. A novel GIT2-BRAF fusion in pilocytic astrocytoma. *Diagn Pathol*. 2017;12(1):82.
69. Brandner S. Molecular Diagnostics of Adult Gliomas in Neuropathological Practice. *Acta Med Acad*. 2021;50(1):29-46.
70. Sekoranza D, Pizem J, Luzar B. An Update on Molecular Genetic Aberrations in Spitz Melanocytic Proliferations: Correlation with Morphological Features and Biological Behavior. *Acta Med Acad*. 2021;50(1):157-74.
71. Liu ZH, Zhu BW, Shi M, Qu YR, He XJ, Yuan HL, et al. Profiling of gene fusion involving targetable genes in Chinese gastric cancer. *World J Gastrointest Oncol*. 2022;14(8):1528-39.
72. Lassche G, van Helvert S, Eijkelenboom A, Tjan MJH, Jansen EAM, van Cleef PHJ, et al. Identification of Fusion Genes and Targets for Genetically Matched Therapies in a Large Cohort of Salivary Gland Cancer Patients. *Cancers (Basel)*. 2022;14(17):4156.
73. Paoli C, Burel-Vandenbos F, Coulomb-l'Hermine A, Cros J, Pondrom M, Kubiniek V, et al. AGAP3: A novel BRAF fusion partner in pediatric pancreatic-type acinar cell carcinoma. *Genes Chromosomes Cancer*. 2022.
74. Penning AJ, Al-Ibraheemi A, Michal M, Larsen BT, Cho SJ, Lockwood CM, et al. Novel BRAF gene fusions and activating point mutations in spindle cell sarcomas with histologic overlap with infantile fibrosarcoma. *Mod Pathol*. 2021;34(8):1530-40.
75. Kao YC, Fletcher CDM, Alaggio R, Wexler L, Zhang L, Sung YS, et al. Recurrent BRAF Gene Fusions in a Subset of Pediatric Spindle Cell Sarcomas: Expanding the Genetic Spectrum of Tumors With Overlapping Features With Infantile Fibrosarcoma. *Am J Surg Pathol*. 2018;42(1):28-38.
76. Hughes CE, Correa H, Benedetti DJ, Smith B, Sumegi J, Bridge J. Second Report of PDE10A-BRAF Fusion in Pediatric Spindle Cell Sarcoma With Infantile Fibrosarcoma-Like Morphology Suggesting PDE10A-BRAF Fusion Is a Recurrent Event. *Pediatric and Developmental Pathology*. 2021;24(6):554-8.
77. Antonescu CR. Emerging soft tissue tumors with kinase fusions: An overview of the recent literature with an emphasis on diagnostic criteria. *Genes Chromosomes Cancer*. 2020;59(8):437-44.
78. Klubickova N, Agaimy A, Hajkova V, Ptakova N, Grossmann P, Steiner P, et al. RNA-sequencing of myxoinflammatory fibroblastic sarcomas reveals a novel SND1::BRAF fusion and 3 different molecular aberrations with the potential to upregulate the TEAD1 gene including SEC23IP::VGLL3 and TEAD1::MRTFB gene fusions. *Virchows Arch*. 2022;481(4):613-20.
79. Vairy S, Jouan L, Bilodeau M, Dormoy-Raclet V, Gendron P, Couture F, et al. Novel PDE10A-BRAF Fusion With Concomitant NF1 Mutation Identified in an Undifferentiated Sarcoma of Infancy With Sustained Response to Trametinib. *JCO Precis Oncol*. 2018;2:1-13.
80. Ogura K, Hosoda F, Arai Y, Nakamura H, Hama N, Totoki Y, et al. Integrated genetic and epigenetic analysis of myxofibrosarcoma. *Nat Commun*. 2018;9(1):2765.
81. Jain P, Silva A, Han HJ, Lang SS, Zhu Y, Boucher K, et al. Overcoming resistance to single-agent therapy for oncogenic BRAF gene fusions via combinatorial targeting of MAPK and PI3K/mTOR signaling pathways. *Oncotarget*. 2017;8(49):84697-713.
82. Domen A, Paesschen CV, Zwaenepoel K, Lambin S, Pauwels P, Rasschaert M, et al. Excellent Response to MEK Inhibition in an AGK-BRAF Gene Fusion Driven Carcinoma: Case Report and Literature Review. *Anticancer Res*. 2022;42(1):373-9.

83. Schrock AB, Zhu VW, Hsieh WS, Madison R, Creelan B, Silberberg J, et al. Receptor Tyrosine Kinase Fusions and BRAF Kinase Fusions are Rare but Actionable Resistance Mechanisms to EGFR Tyrosine Kinase Inhibitors. *J Thorac Oncol.* 2018;13(9):1312-23.
84. Yu Y, Yu M, Li Y, Zhou X, Tian T, Du Y, et al. Rapid response to monotherapy with MEK inhibitor trametinib for a lung adenocarcinoma patient harboring primary SDN1-BRAF fusion: A case report and literature review. *Front Oncol.* 2022;12:945620.
85. Fenor MD, Ruiz-Llorente S, Rodriguez-Moreno JF, Caldeiras E, Torregro JC, Sevillano-Fernandez E, et al. MEK inhibitor sensitivity in BRAF fusion-driven prostate cancer. *Clin Transl Oncol.* 2022.
86. Hendifar A, Blais EM, Wolpin B, Subbiah V, Collisson E, Singh I, et al. Retrospective Case Series Analysis of RAF Family Alterations in Pancreatic Cancer: Real-World Outcomes From Targeted and Standard Therapies. *JCO Precis Oncol.* 2021;5:PO.20.00494.
87. Grisham RN, Moore KN, Gordon MS, Harb W, Cody G, Halpenny DE, et al. Phase Ib Study of Binimetinib with Paclitaxel in Patients with Platinum-Resistant Ovarian Cancer: Final Results, Potential Biomarkers, and Extreme Responders. *Clin Cancer Res.* 2018;24(22):5525-33.
88. Subbiah V, Westin SN, Wang K, Araujo D, Wang WL, Miller VA, et al. Targeted therapy by combined inhibition of the RAF and mTOR kinases in malignant spindle cell neoplasm harboring the KIAA1549-BRAF fusion protein. *J Hematol Oncol.* 2014;7:8.
89. Ros J, Baraibar I, Sardo E, Mulet N, Salva F, Argiles G, et al. BRAF, MEK and EGFR inhibition as treatment strategies in BRAF V600E metastatic colorectal cancer. *Ther Adv Med Oncol.* 2021;13:1758835921992974.
90. Elisei R, Viola D, Torregrossa L, Giannini R, Romei C, Ugolini C, et al. The BRAF(V600E) mutation is an independent, poor prognostic factor for the outcome of patients with low-risk intrathyroid papillary thyroid carcinoma: single-institution results from a large cohort study. *J Clin Endocrinol Metab.* 2012;97(12):4390-8.
91. Pelizzo MR, Dobrinja C, Casal Ide E, Zane M, Lora O, Toniato A, et al. The role of BRAF(V600E) mutation as poor prognostic factor for the outcome of patients with intrathyroid papillary thyroid carcinoma. *Biomed Pharmacother.* 2014;68(4):413-7.
92. Barbour AP, Tang YH, Armour N, Dutton-Regester K, Krause L, Loffler KA, et al. BRAF mutation status is an independent prognostic factor for resected stage IIIB and IIIC melanoma: implications for melanoma staging and adjuvant therapy. *Eur J Cancer.* 2014;50(15):2668-76.
93. Zhang Q, Liu SZ, Zhang Q, Guan YX, Chen QJ, Zhu QY. Meta-Analyses of Association Between BRAF(V600E) Mutation and Clinicopathological Features of Papillary Thyroid Carcinoma. *Cell Physiol Biochem.* 2016;38(2):763-76.
94. Proietti I, Skroza N, Michelini S, Mambrin A, Balduzzi V, Bernardini N, et al. BRAF Inhibitors: Molecular Targeting and Immunomodulatory Actions. *Cancers (Basel).* 2020;12(7):1823.
95. Poulikakos PI, Sullivan RJ, Yaeger R. Molecular Pathways and Mechanisms of BRAF in Cancer Therapy. *Clin Cancer Res.* 2022.
96. Ascierto PA, McArthur GA, Dreno B, Atkinson V, Liszkay G, Di Giacomo AM, et al. Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. *Lancet Oncol.* 2016;17(9):1248-60.
97. Long GV, Flaherty KT, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, et al. Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study. *Ann Oncol.* 2017;28(7):1631-9.
98. Welsh SJ, Rizos H, Scolyer RA, Long GV. Resistance to combination BRAF and MEK inhibition in metastatic melanoma: Where to next? *Eur J Cancer.* 2016;62:76-85.
99. Michielin O, van Akkooi ACJ, Ascierto PA, Dummer R, Keilholz U, clinicalguidelines@esmo.org EGCEa. Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up dagger. *Ann Oncol.* 2019;30(12):1884-901.
100. Gautschi O, Milia J, Cabarro B, Bluthgen MV, Besse B, Smit EF, et al. Targeted Therapy for Patients with BRAF-Mutant Lung Cancer: Results from the European EURAF Cohort. *J Thorac Oncol.* 2015;10(10):1451-7.
101. Wagle N, Van Allen EM, Treacy DJ, Frederick DT, Cooper ZA, Taylor-Weiner A, et al. MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition. *Cancer Discov.* 2014;4(1):61-8.
102. Van Allen EM, Wagle N, Sucker A, Treacy DJ, Johannessen CM, Goetz EM, et al. The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. *Cancer Discov.* 2014;4(1):94-109.
103. Turajlic S, Furney SJ, Stamp G, Rana S, Ricken G, Oduko Y, et al. Whole-genome sequencing reveals complex mechanisms of intrinsic resistance to BRAF inhibition. *Ann Oncol.* 2014;25(5):959-67.
104. Kakadia S, Yarlagadda N, Awad R, Kundranda M, Niu J, Naraev B, et al. Mechanisms of resistance to BRAF and MEK inhibitors and clinical update of US Food and Drug Administration-approved targeted therapy in advanced melanoma. *Onco Targets Ther.* 2018;11:7095-107.
105. Chapman PB. Mechanisms of resistance to RAF inhibition in melanomas harboring a BRAF mutation. *Am Soc Clin Oncol Educ Book.* 2013.

106. Vellano CP, White MG, Andrews MC, Chelvanambi M, Witt RG, Daniele JR, et al. Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy. *Nature*. 2022;606(7915):797-803.
107. Facchinetti F, Lacroix L, Mezquita L, Scoazec JY, Lorient Y, Tselikas L, et al. Molecular mechanisms of resistance to BRAF and MEK inhibitors in BRAF(V600E) non-small cell lung cancer. *Eur J Cancer*. 2020;132:211-23.
108. Khaliq M, Fallahi-Sichani M. Epigenetic Mechanisms of Escape from BRAF Oncogene Dependency. *Cancers (Basel)*. 2019;11(10):1480.
109. Hall RD, Kudchadkar RR. BRAF mutations: signaling, epidemiology, and clinical experience in multiple malignancies. *Cancer Control*. 2014;21(3):221-30.
110. Garbe C, Amaral T, Peris K, Hauschild A, Arenberger P, Basset-Seguín N, et al. European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2022. *Eur J Cancer*. 2022;170:256-84.
111. Dummer R, Hauschild A, Guggenheim M, Keilholz U, Pentheroudakis G, Group EGW. Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol*. 2012;23 Suppl 7:vii86-91.
112. Santiago-Walker A, Gagnon R, Mazumdar J, Casey M, Long GV, Schadendorf D, et al. Correlation of BRAF Mutation Status in Circulating-Free DNA and Tumor and Association with Clinical Outcome across Four BRAFi and MEKi Clinical Trials. *Clin Cancer Res*. 2016;22(3):567-74.
113. Giunta EF, De Falco V, Vitiello PP, Guerrera LP, Suarato G, Napolitano R, et al. Clinical Utility of Liquid Biopsy to Detect BRAF and NRAS Mutations in Stage III/IV Melanoma Patients by Using Real-Time PCR. *Cancers (Basel)*. 2022;14(13):3053.
114. Seremet T, Jansen Y, Planken S, Njimi H, Delaunoy M, El Housni H, et al. Undetectable circulating tumor DNA (ctDNA) levels correlate with favorable outcome in metastatic melanoma patients treated with anti-PD1 therapy. *J Transl Med*. 2019;17(1):303.
115. Rutkowski P, Pauwels P, Kerger J, Jacobs B, Maertens G, Gadeyne V, et al. Characterization and Clinical Utility of BRAF(V600) Mutation Detection Using Cell-Free DNA in Patients with Advanced Melanoma. *Cancers (Basel)*. 2021;13(14):3591.
116. Long-Mira E, Ilie M, Chamorey E, Leduff-Blanc F, Montaudie H, Tanga V, et al. Monitoring BRAF and NRAS mutations with cell-free circulating tumor DNA from metastatic melanoma patients. *Oncotarget*. 2018;9(90):36238-49.
117. Vanni I, Tanda ET, Spagnolo F, Andreotti V, Bruno W, Ghiorzo P. The Current State of Molecular Testing in the BRAF-Mutated Melanoma Landscape. *Front Mol Biosci*. 2020;7:113.
118. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. *N Engl J Med*. 2011;364(26):2507-16.
119. Morash M, Mitchell H, Beltran H, Elemento O, Pathak J. The Role of Next-Generation Sequencing in Precision Medicine: A Review of Outcomes in Oncology. *J Pers Med*. 2018;8(3):30.
120. Freedman AN, Klabunde CN, Wiant K, Enewold L, Gray SW, Filipinski KK, et al. Use of Next-Generation Sequencing Tests to Guide Cancer Treatment: Results From a Nationally Representative Survey of Oncologists in the United States. *JCO Precis Oncol*. 2018;2:1-13.
121. Anwar MA, Murad F, Dawson E, Abd Elmageed ZY, Tsumagari K, Kandil E. Immunohistochemistry as a reliable method for detection of BRAF-V600E mutation in melanoma: a systematic review and meta-analysis of current published literature. *J Surg Res*. 2016;203(2):407-15.
122. Day F, Muranyi A, Singh S, Shanmugam K, Williams D, Byrne D, et al. A mutant BRAF V600E-specific immunohistochemical assay: correlation with molecular mutation status and clinical outcome in colorectal cancer. *Target Oncol*. 2015;10(1):99-109.
123. Bledsoe JR, Kamionek M, Mino-Kenudson M. BRAF V600E immunohistochemistry is reliable in primary and metastatic colorectal carcinoma regardless of treatment status and shows high intratumoral homogeneity. *Am J Surg Pathol*. 2014;38(10):1418-28.
124. Pyo JS, Sohn JH, Kang G. Diagnostic Accuracy of BRAF Immunohistochemistry in Colorectal Cancer: a Meta-Analysis and Diagnostic Test Accuracy Review. *Pathol Oncol Res*. 2016;22(4):831-7.
125. Pyo JS, Sohn JH, Kang G. BRAF Immunohistochemistry Using Clone VE1 is Strongly Concordant with BRAF(V600E) Mutation Test in Papillary Thyroid Carcinoma. *Endocr Pathol*. 2015;26(3):211-7.
126. Zhu X, Luo Y, Bai Q, Lu Y, Lu Y, Wu L, et al. Specific immunohistochemical detection of the BRAF V600E mutation in primary and metastatic papillary thyroid carcinoma. *Exp Mol Pathol*. 2016;100(1):236-41.
127. Parker KG, White MG, Cipriani NA. Comparison of Molecular Methods and BRAF Immunohistochemistry (VE1 Clone) for the Detection of BRAF V600E Mutation in Papillary Thyroid Carcinoma: A Meta-Analysis. *Head Neck Pathol*. 2020;14(4):1067-79.
128. Rangel-Pozzo A, Dettori T, Virginia Frau D, Etzi F, Gartner J, Fisher G, et al. Three-dimensional telomere profiles in papillary thyroid cancer variants: A pilot study. *Bosn J Basic Med Sci*. 2022;22(3):481-7.
129. Andrulis M, Penzel R, Weichert W, von Deimling A, Capper D. Application of a BRAF V600E mutation-specific antibody for the diagnosis of hairy cell leukemia. *Am J Surg Pathol*. 2012;36(12):1796-800.

130. Wang XJ, Kim A, Li S. Immunohistochemical analysis using a BRAF V600E mutation specific antibody is highly sensitive and specific for the diagnosis of hairy cell leukemia. *Int J Clin Exp Pathol.* 2014;7(7):4323-8.
131. Turashvili G, Grisham RN, Chiang S, DeLair DF, Park KJ, Soslow RA, et al. BRAF(V)(600E) mutations and immunohistochemical expression of VE1 protein in low-grade serous neoplasms of the ovary. *Histopathology.* 2018;73(3):438-43.
132. Gatalica Z, Vranic S, Rose I, Teresi P, Feldman R, Bender RP. Concordance of Anti-BRAF p.V600E immunohistochemistry with BRAF Gene Sequence in Solid Tumors Carrying Diverse BRAF Mutations. *Mod Pathol.* 2016;29:454A.
133. Bennema AN, Schendelaar P, Seggers J, Haadsma ML, Heineman MJ, Hadders-Algra M. Predictive value of general movements' quality in low-risk infants for minor neurological dysfunction and behavioural problems at preschool age. *Early Hum Dev.* 2016;94:19-24.
134. Uguen A, Uguen M. VE1 Immunohistochemistry Fails to Detect Most of the Non-BRAFV600E Mutations in Melanoma. *Appl Immunohistochem Mol Morphol.* 2016;24(10):e98-9.
135. Ilie M, Long E, Hofman V, Dadone B, Marquette CH, Mouroux J, et al. Diagnostic value of immunohistochemistry for the detection of the BRAFV600E mutation in primary lung adenocarcinoma Caucasian patients. *Ann Oncol.* 2013;24(3):742-8.
136. Lenci N, Francesco P, Scarciglia E, Fiorentino V, Schino M, Palermo G, et al. Metanephric adenoma with BRAF V600K mutation and a doubtful radiological imaging: pitfalls in the diagnostic process. *Med Mol Morphol.* 2021;54(2):187-91.
137. Calio A, Eble JN, Hes O, Martignoni G, Harari SE, Williamson SR, et al. Distinct clinicopathological features in metanephric adenoma harboring BRAF mutation. *Oncotarget.* 2017;8(33):54096-105.
138. Phan DAT, Phung GB, Duong TT, Hoang AV, Ngo QD, Trinh DTN, et al. The Value of BRAF VE1 Immunorepression in Pediatric Langerhans Cell Histiocytosis. *Fetal Pediatr Pathol.* 2022;41(4):558-67.
139. Martins-de-Barros AV, Anjos RSD, Silva CCG, Silva E, Araujo F, Carvalho MV. Diagnostic accuracy of immunohistochemistry compared with molecular tests for detection of BRAF V600E mutation in ameloblastomas: Systematic review and meta-analysis. *J Oral Pathol Med.* 2022;51(3):223-30.
140. Kelppe J, Thoren H, Ristimaki A, Haglund C, Sorsa T, Hagstrom J. BRAF V600E expression in ameloblastomas-A 36-patient cohort from Helsinki University Hospital. *Oral Dis.* 2019;25(4):1169-74.